FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Julia A. Beaver, Chana Weinstock et al.|Clinical Cancer Research|2020Cited by 186
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Richard Pazdur, Lynn Howie et al.|Clinical Cancer Research|2018Cited by 133
Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center StudyTongpeng Xu, Yue Zhou, Meizhen Hu et al.|Annals of Surgical Oncology|2024Cited by 8
[Correlative analysis of degenerative lumbar scoliosis and osteoporosis].Dao-Yu Huang, Jun Liu, Yajun Shen et al.|PubMed|2019Cited by 6
Abstract 5615: ALRN-0192519 is a potent and selective EGFR L858R mutation inhibitor that demonstrates anti-cancer activity in preclinical cancer models as monotherapy or in combination with osimertinibJiaqi Liang, Lina Gu, Yezhen Zhang et al.|Cancer Research|2025Cited by 0